PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Biotechnology
Healthcare
Get real-time and historical exchange rates for any currency!
Get real-time and historical stock ticker prices for US stocks!
Translate cryptic bank transactions into merchants with logos, address and more!
Brought to you by Synth, a modern fintech API for modern businesses